The therapeutic armamentarium of chronic myeloid leukemia (CML) has greatly improved after small molecule tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 became available. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.